Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
| Stock | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| HDSNHudson Technologies Inc. | Hartree Partners LP10% Owner | $1.62M | Added | |||
| Confirmed July 5 (Saturday) EDGAR filing. Part of 3-tranche accumulation: 204,789 shares Jun 30 + 288,111 shares Jul 1 + 271,302 shares Jul 2 = 764,202 total shares (~$4.5M). Avg buy $5.97; now $5.99 (+0.3%). Hartree stake now ~11.8%. EPA HFC phase-down tailwind. | ||||||
| WBXWallbox N.V. | Pedro Alonso AgueraDirector | $1.36M | Added | |||
| Bought Jun 30 at $2.72 avg, same day Spanish court finalized €15.8M restructuring. Now $4.16 (+52.9%). Cluster buy alongside CEO Escorsa. Post-restructuring insider conviction. | ||||||
| NVCTNuvectis Pharma Inc. | Marlio Charles Mosseri10% Owner | $916K | Added | |||
| Bought Jun 30 at $18.32 avg (range $18.29–$18.32). Now $19.57 (+6.8%). Post-offering cluster buy alongside CEO Bentsur ($250K). Precision oncology biotech. Total insider cluster ~$1.17M. | ||||||
| WBXWallbox N.V. | Enric Asuncion EscorsaCEO | $886K | Added | |||
| Bought Jun 30 at $2.72 avg, same day as Director Aguera. Now $4.16 (+52.9%). Combined WBX insider cluster (CEO + Director) = $2.25M. Post-restructuring conviction buy. | ||||||
| JCTCJewett-Cameron Trading Co. Ltd. | Adam James Bradley10% Owner | $806K | Added | |||
| Purchased Jun 29 at $2.28 avg by AJB Investment Fund II LP, AJB Capital LLC, Adam James Bradley, and Melinda Hodges Bradley collectively. AJB group now ~10.9% of JCTC. Now $2.56 (+12.3%). Block size unusual relative to market cap — possible strategic intent. | ||||||
| FTHFaeth Therapeutics Inc. | Brian C. StephensonCFO | $326K | Added | |||
| Purchases Jun 29–Jul 1 at $22.95–$24.98 range (~$23.92 avg) via Brian Stephenson Revocable Trust. Now $22.92 (-4.2%). Sixth consecutive week of open-market CFO buying — cumulative personal investment >$1M. Precision oncology (formerly Sensei Biotherapeutics). | ||||||
| BOLDBoundless Bio Inc. | Kevin Tang10% Owner | $269K | Added | |||
| Purchased Jun 30–Jul 2 at $2.49–$2.54 avg via Tang Capital Management LLC. Tang stake now ~11.3% (2.64M shares). Now $2.50 (0.0%). Extrachromosomal DNA (ecDNA) oncology platform. | ||||||
| NVCTNuvectis Pharma Inc. | Ron BentsurChairman & CEO | $250K | Added | |||
| Bought at $20.00 (public offering price, Jun 29–Jul 1 window). Now $19.57 (-2.2%). Cluster buy alongside 10% owner Mosseri. Combined NVCT insider cluster = $1.17M. Note: may be offering-price buy (verify transaction code). | ||||||
Scanned the last 24 hours of EDGAR Form 4 filings. 8 qualifying buys (≥ $250K, transaction type P) totalling $6.44M. Note: July 4 (Independence Day) and July 5–6 (weekend) produced minimal EDGAR traffic; this batch spans June 29 – July 5, covering the complete holiday-shortened week with July 5 (Saturday) being the only confirmed new filer (Hartree/HDSN).
Holiday-week context: The July 4 federal holiday (Friday) compressed the trading week to 3.5 days. Hartree Partners is the sole confirmed weekend filer (Jul 5, Saturday). Remaining filings are from July 1–3 trailing edge. Next batch of Form 4s for July 3 trades is due by July 7–8.
WBX cluster is the standout of the week: Wallbox CEO + Director both bought at $2.72 on June 30, the same day the Spanish court finalized the company's debt-to-equity restructuring. The stock has surged +53% to $4.16 as of this scan — both insiders are already deeply in the green on 6-day-old positions.
Refrigerant play (HDSN): Hartree accumulated 764K shares (~$4.5M total) across three days, pushing its stake past 11.8%. Hudson Technologies reclaims and recycles HFCs; EPA's accelerated phase-down schedule makes reclaimed refrigerant increasingly scarce and valuable.
NVCT biotech cluster: CEO and a major shareholder both bought within days of a $20 public offering — combined ~$1.17M invested. Insiders frequently buy alongside offerings they believe are priced at a discount to intrinsic value.
Serial CFO buyer (FTH): Faeth Therapeutics (precision oncology, formerly Sensei Biotherapeutics) has a new management team that has been buying aggressively since installation. The CFO's 6-week streak of open-market buys through a personal revocable trust is an unusually strong repeated conviction signal.
JCTC strategic stake: AJB Capital's $806K block lifts their JCTC stake to ~10.9% — likely the precursor to a board seat demand or takeout offer on this small-cap fencing and industrial products company.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.